Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AstraZeneca's PARP inhibitor Lynparza becomes first US FDA-approved drug for pancreatic cancer based on progression-free survival endpoint, providing regulatory precedent for other sponsors to use that development approach; all other pancreatic cancer drugs had been approved based on an overall survival benefit.
The US Food and Drug Administration has opened the door for sponsors to use a progression-free survival (PFS) endpoint in developing pancreatic cancer drugs with the agency's 27 December 2019 supplemental approval of AstraZeneca PLC's Lynparza (olaparib) for the disease.
Lynparza, a PARP inhibitor, is now specifically labeled for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. It's the first FDA-approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer. (Also see "Lynparza Gets US OK For Pancreatic Cancer " - Scrip, 30 Dec, 2019.)
The indication is Lynparza's fifth overall; the drug also holds three indications in ovarian cancer and one in breast cancer.
AstraZeneca opted to use PFS as the primary endpoint in its pivotal POLO trial to support the pancreatic cancer indication despite advice from FDA to use overall survival (OS). The agency generally recommends that sponsors developing new pancreatic cancer drugs use OS as the primary endpoint due to concerns regarding the accuracy of tumor measurement in the disease. OS data from POLO were not yet mature at the time of the PFS analysis. (Also see "AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte. " - Pink Sheet, 15 Dec, 2019.)
However, the Oncologic Drugs Advisory Committee narrowly voted in favor of approval for the indication by a 7-5 margin at a 17 December 2019 meeting. Panelists agreed with the FDA's view that Lynparza's overall impact on PFS was clinically modest, although a small majority felt the drug demonstrated meaningful benefit in a small subset of patients and that it should be approved. (Also see " Lynparza For Pancreatic Cancer: ODAC's Narrow Support Leaves US FDA In Quandary" - Pink Sheet, 17 Dec, 2019.)
AstraZeneca will submit the final OS analysis and datasets to the agency as part of a 506B postmarketing commitment. According to the approval letter, AstraZeneca will complete the trial by December 2020 and submit the final report by June 2021.
Nevertheless, sponsors now have regulatory precedent to support pancreatic cancer applications with a PFS primary endpoint, which is generally assessed earlier and with a smaller patient sample size compared with survival endpoints.
According to Biomedtracker, there are nearly 20 pancreatic cancer candidates in Phase II and that have not yet begun a pivotal trial. The sponsors of these products may have the option of studying their candidates using a PFS primary endpoint in pivotal development.
Phase II Pancreatic Cancer Pipeline
The following candidates are in Phase II development for pancreatic cancer and have not yet been tested in a pivotal trial.
Source: Biomedtracker
Pink Sheet: global policy and regulatory coverage
Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie Sanders urged FDA to address price of Catalyst's Firdapse (amifampridine).
Pink Sheet: global policy and regulatory coverage
By Brenda Sandburg 16 Feb 2020
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based...
Pink Sheet: global policy and regulatory coverage
By Brenda Sandburg 16 Feb 2020
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district...
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, you stay on top of breaking events, what’s in the drugs pipeline, upcoming milestones, clinical trial results and their impact on the markets you care about
A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.
Looking for more products Product Finder
